Shopping Cart
Remove All
Your shopping cart is currently empty
Lazabemide (Ro 19-6327) is a selective and reversible monoamine oxidase B (MAO-B) inhibitor with IC50 values of 0.03 μM for MAO-B and >100 μM for MAO-A.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $50 | 6-8 weeks | 6-8 weeks | |
| 25 mg | $108 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $182 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $273 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $47 | 6-8 weeks | 6-8 weeks |
| Description | Lazabemide (Ro 19-6327) is a selective and reversible monoamine oxidase B (MAO-B) inhibitor with IC50 values of 0.03 μM for MAO-B and >100 μM for MAO-A. |
| Targets&IC50 | MAO-B:30 nM |
| In vitro | LAZABEMIDE is selective, high-affinity ligands for enzymes.?KD and Bmax values for 3H-Ro 41 1049 in rat cerebral cortex were 10.7 nM and 7.38 pmol/mg protein, respectively, and for 3H-Ro 19 6327 were 18.4 nM and 3.45 pmol/mg protein, respectively.?In accordance with their potencies as enzyme inhibitors, binding to MAO-A and MAO-B was competitively inhibited by clorgyline (IC50 = 1.4 nM) and L-deprenyl (selegiline;?IC50 = 8.0 nM), respectively[1]. |
| In vivo | Lazabemide is a reversible inhibitor of monoamine oxidase B (MAO-B) with IC50 values of 0.48 and 1.5 μM measured in platelets of human subjects ages 19-36 and 60-78, respectively[2]. |
| Synonyms | Ro 19-6327 |
| Molecular Weight | 199.64 |
| Formula | C8H10ClN3O |
| Cas No. | 103878-84-8 |
| Relative Density. | 1.286g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 34 mg/mL (170.31 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 0.5 mg/mL (2.5 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.